Yesterday, the award ceremony for the 8th Greater Bay Area Biotechnology Innovation Top 50 was held in Shenzhen. The event, hosted by the Zhongchuang Industry Research Institute and organized by Guangdong Medical Valley, has been successfully held for eight consecutive years. It has garnered widespread attention and coverage from government departments, academic experts, media, and biotech companies. Numerous top experts, investors, entrepreneurs, and media representatives in the biotechnology industry gathered in Shenzhen to witness the unveiling of this year's Top 50 enterprises.
After four months of review and field visits, SIGNET has once again been selected for the Top 50 list due to its excellent clinical progress in drug pipelines and industry influence, earning the distinguished honor of being named a "Pioneer Enterprise" in the Top 50 Biotechnology Innovations in the Guangdong-Hong Kong-Macao Greater Bay Area.
Signet Therapeutics isGlobal Pioneer in "Organoid+AI"-Empowered Innovative Targeted Drug R&D Model, a national high-tech enterprise and a specialized and innovative enterprise. The company's founding team is composed of outstanding talents from top institutions such as Harvard University, MIT, and the Chinese Academy of Sciences. As the first/corresponding author, they have published more than 20 groundbreaking research achievements in the field of gastric cancer and esophageal cancer in journals with an impact factor of over 20, such as Nature, Nature Medicine, and Cancer Cell, making them a global leader in the research of gastric cancer and esophageal cancer. Since its establishment in Shenzhen at the end of 2020, the company has completed nearly 220 million yuan in financing and project funding, and holds more than 40 core intellectual properties.
The company currently has four first-in-class drug pipelines and an organoid platform, with the core pipeline being...SIGX1094R as the world's first targeted drug for diffuse gastric cancer, successively obtained the IND approval from the U.S. FDA and China NMPA, and received the U.S. FDA Orphan Drug Designation (ODD) and Fast Track Designation (FTD). The drug wasNominated for the 2025 Galien Award, Known as the "Nobel Prize in Medicine", which is currently in Phase I clinical trials at the Peking University Cancer Hospital. This pipeline is also the world's first drug pipeline advanced to the clinical stage through the "Organoid+AI" technology platform.
Since its establishment at the end of 2020, the company's forward-looking strategic layout of the "Organoid+AI" empowered technology system for innovative targeted cancer drug research and development has gained international authoritative recognition. It was reported on the homepage of the globally renowned biotech media Fierce Biotech and evaluated as "NEXT Generation Paradigm for Cancer Drug DevelopmentIn April 2025, the U.S. FDA officially issued a statement clearly supporting the gradual replacement of traditional animal experiments with organoid and AI technologies, fully verifying the foresight and scientific nature of the company's technical layout from four years ago.
1
END
1
